Free Trial

Ligand Pharmaceuticals (LGND) SEC Filings & 10K Form

Ligand Pharmaceuticals logo
$150.06 +3.74 (+2.56%)
Closing price 04:00 PM Eastern
Extended Trading
$146.39 -3.67 (-2.45%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Ligand Pharmaceuticals SEC Filings

DateFilerForm TypeView
08/07/2025
6:04 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/01/2025
3:04 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/11/2025
5:17 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2025
4:08 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/03/2025
8:28 AM
Ligand Pharmaceuticals (Reporting)
Pelthos Therapeutics Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
07/03/2025
8:33 AM
Ligand Pharmaceuticals (Reporting)
Pelthos Therapeutics Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2025
6:31 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2025
6:32 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2025
6:32 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2025
6:03 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 3/A
07/02/2025
6:10 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/24/2025
7:29 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025
4:07 PM
Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/12/2025
4:51 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:39 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:39 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:20 PM
Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:21 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:21 PM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:21 PM
Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:24 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
5:49 PM
Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/02/2025
7:05 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2025
7:06 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2025
11:31 AM
JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
05/13/2025
7:04 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2025
7:05 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2025
6:06 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2025
5:08 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/16/2025
8:34 AM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2025
5:54 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2025
5:55 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2025
5:55 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/28/2025
3:02 PM
Ligand Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/27/2025
6:06 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/19/2025
7:44 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
7:37 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
7:38 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2025
11:36 AM
JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
12/26/2024
7:32 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2024
7:19 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
BREAKING: The House just passed 3 pro-crypto bills! (Ad)

THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.

Discover the under-the-radar project I believe will skyrocket as a result.
12/06/2024
6:55 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2024
7:05 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
3:44 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2024
2:19 PM
JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
11/08/2024
4:34 PM
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
11/07/2024
6:11 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/01/2024
3:07 PM
Ligand Pharmaceuticals (Subject)
MACQUARIE GROUP LTD (Filed by)
Form SC 13G/A
09/25/2024
7:54 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2024
6:41 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2024
6:41 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/23/2024
4:27 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/23/2024
4:30 PM
Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/20/2024
5:12 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/20/2024
4:39 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/19/2024
4:50 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2024
6:55 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/30/2024
8:00 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/30/2024
7:56 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2024
3:39 PM
Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/26/2024
7:15 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2024
5:05 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2024
4:21 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/09/2024
4:52 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/09/2024
4:16 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:LGND) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners